BURCON NUTRASCIENCE CORP Share Price - BU, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(CVE:BU, BU.V)

Watchlist/Portfolio Follow

BURCON NUTRASCIENCE CORP
www.burcon.ca

Deal BURCON NUTRASCIENCE CORP Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

A research and development company developing a portfolio of composition, application and process patents around its plant protein extraction and purification technology.

Recent Sector News

Update - Tissue Regenix eyes US wound care market through tissue bank partnership

Community Tissue Service is one of the largest human tissue banks in the US and distributes over 230,000 grafts every year.
UPDATE: Silence Therapeutics cancer drug successfully negotiates safety hurdle first time

Silence Therapeutics said it has successfully negotiated the initial safety assessment of its cancer drug Atu027
Alliance Pharma deal an important step towards internationalisation, says City research house

The latest addition to the Alliance Pharma medicine chest represents an “important step to the internationalisation of the group”, according to a City research house.
Alliance Pharma's US$11.5mln acquisition will be immediately earnings enhancing

Alliance Pharma has added to its medicine cabinet with the US$11.5mln deal to acquire full ownership of obstetric drug Syntometrine from Swiss giant Novartis. Funded via a mix of internally generated cash and debt from the firm’s acquisition facility, the transaction will be immediately earning enhancing.
Immunotherapies offer hope to cancer patients and investors

Immunotherapies that use the body’s immune system to eliminate or slow the growth of the disease are transforming the world’s second largest killer into a chronic but treatable ailment.
UPDATE: ImmuPharma strengthens hand with £50mln financing deal

ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune disease lupus. The five-year funding package will be provided by Darwin Strategic, owned by Henderson Global Investors.